

## Program

---

09:00-09:10 Welcome and introduction  
Thomas Brüning, IPA, Bochum, Germany

### **Bladder cancer screening: Whom to screen and where do we stand with protein-based markers?**

09:10-09:30 Bladder cancer screening – The economic perspective  
Yair Lotan, University of Texas, Dallas, USA

09:30-09:50 Protein-based tumor markers and bladder cancer –  
The clinical perspective  
Bernd Schmitz-Dräger, for the International Bladder Cancer Network,  
Germany

09:50-10:10 NMP22 as urine-based approved tumor marker –  
Results from the prospective cohort UroScreen  
Gerhard Feil, Department of Urology, Eberhard Karls University  
Tübingen, Germany

10:10-10:30 Survivin as a urine-based non-approved tumor marker –  
Results from UroScreen  
Georg Johnen, IPA, Bochum

---

10:30-10:50 Coffee break

---

10:50-11:10 Early results of bladder-cancer screening in heavy smokers  
Hannes Steiner, University Innsbruck, Austria

### **Urine proteomics: Challenges for research networks**

11:10-11:30 Urine proteomics – Translational research in networks  
NN

11:30-11:50 Urine proteomics – Workflow and technologies:  
pitfalls and challenges  
Antonia Vlahou, Bioacademy Athens, Greece

## Program

---

11:50-12:10 Development of urinary peptide markers –  
The perspective of biotechnology  
Harald Mischak, Mosaiques diagnostics, Germany

---

12:10-13:10 Lunch break

---

13:10-13:30 PURE – A new platform for protein-based markers  
in Europe  
Volker Harth, IPA Bochum, Germany

13:30-13:50 National prospective cohort studies:  
Urine sampling, biobanking and -omics technologies  
for the retrospective performance of markers  
Thomas Illig, HHC München, Germany

### **Standard Operating Protocols: Which steps need standards?**

13:50-14:10 A ‘multi-purpose’ SOP for urine collection and storage  
in prospective cohort studies  
Gereon Poschmann, Ruhr University Bochum, Germany

14:10-14:30 Peptides, proteins and protein identification:  
challenges of analysing, storing and handling large  
datasets  
Rolf Apweiler, European Bioinformatics Institute, Hinxton, UK

14:30-14:50 Assessing potential confounders for urine-based markers  
Beate Pesch, IPA, Bochum, Germany


---

14:50-15:20 Coffee break

---

15:20-15:40 From proteomics to tumor markers  
NN

15:40-16:40 Future research on urinary tumor markers –  
Synergies between technological platforms, clinicians,  
cohort studies and biotechnology  
**Round table discussion**



## Symposium

# “Urine Proteomics, Proteine-based Tumor Markers and Bladder Cancer”

Organized by Institute for Prevention and Occupational Medicine  
of the German Social Accident Insurance  
Institute of Ruhr University Bochum (IPA)

Please register until October 8, 2010

Contact: Beate Pesch

IPA  
Bürkle-de-la-Camp Platz 1  
44789 Bochum

Phone: +49 234 3024536

Fax: +49 234 3024581

E-Mail: [pesch@ipa-dguv.de](mailto:pesch@ipa-dguv.de)

November 23, 2010

Lecture hall  
Bochum, Germany